Table 2 Results of immunohistochemical analysis and treatment outcomes of ICI therapy.

From: Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients

Patient

HLA-DR

CD8

TIA-1

T cell infiltration pattern

HLA class I

PD-L1

FoxP3

Immunohistogram

Response to ICI

PFS

CSS

Positive area (%)

Score

Cells/HPF

Score

Cells/HPF

Score

 

Score

Intensity :positive area (%)

Score

Positive area (%)

Score

Cells/HPF

Score

Months

Months

RCC01

60

3

288

3

112

3

Inflamed

3

3:100

3

60

3

5

1

Immune-hot

CR

18.8

18.8

RCC02

50

3

102

3

70

3

Inflamed

3

3:80, 1:20

3

60

3

5

1

Immune-hot

PR

36.5

36.5

RCC03

10

0

50

3

14

2

Excluded

1

2:60, 1:40

2

0

0

0

0

Immune-cold

PR

23.0

52.0

RCC04

50

3

88

3

65

3

Partially inflamed

2

3:50, 1:50

3

30

2

0

0

Immune-hot

CR

30.1

30.1

RCC05

50

3

324

3

172

3

Partially inflamed

2

3:100

3

5

1

15

2

Immune-hot

SD

20.0

28.6

RCC06

80

3

138

3

160

3

Inflamed

3

3:80, 1:20

3

10

1

5

1

Immune-hot

CR

26.2

26.2

RCC07

0

0

9

1

7

1

Excluded

1

3:20, 1:80

1

100

3

0

0

Immune-cold

PR

25.4

25.4

UTUC01

0

0

8

1

3

1

Desert

0

2:30, 1:70

1

0

0

5

0

Immune-cold

PD

1.3

1.3

UTUC02

50

3

114

3

56

3

Partially inflamed

2

3:70, 2:30

3

60

3

10

1

Immune-hot

PR

17.9

17.9

UTUC03

0

0

28

2

13

2

Inflamed

3

3:70, 2:30

3

0

0

0

0

Immune-cold

PD

1.9

13.9

UTUC04

5

0

16

2

2

1

Desert

0

3:20, 0:80

0

5

1

5

1

Immune-cold

PD

0.5

1.6

UTUC05

10

0

29

2

11

2

Partially inflamed

2

3:80, 2:20

3

5

1

5

1

Immune-cold

PD

0.1

1.4

BUC01

0

0

81

3

54

3

Excluded

1

3:100

3

5

1

20

2

Immune-cold

PR

15.4

15.4

BUC02

20

1

82

3

31

3

Partially inflamed

2

3:50, 1:50

3

10

1

5

1

Immune-hot

SD

12.7

17.1

BUC03

0

0

32

3

13

2

Partially inflamed

2

3:80, 1:20

3

5

1

5

1

Immune-cold

SD

11.2

22.2

BUC04

70

3

122

3

63

3

Inflamed

3

3:80, 1:20

3

60

3

20

2

Immune-hot

CR

43.8

43.8

BUC05

0

0

8

1

5

1

Desert

0

3:30, 0:70

0

0

0

0

0

Immune-cold

PD

1.3

3.3

BUC06

0

0

40

3

18

2

Excluded

1

2:20, 0:80

0

30

2

0

0

Immune-cold

PD

1.2

2.8

  1. RCC, renal cell carcinoma; UTUC, upper tract urothelial carcinoma; BUC, bladder urothelial carcinoma; ICI, immune checkpoint inhibitor, PFS, progression free survival; CSS, cancer specific survival.